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Abstract
Background: Blood pressure (BP) is poorly controlled among a large proportion of hypertensive outpatients.
Innovative models of care are therefore needed to improve BP control. The Team-Based Care for improving
Hypertension management (TBC-HTA) study aims to evaluate the effect of a team-based care (TBC) interprofessional
intervention, involving nurses, community pharmacists and physicians, on BP control of hypertensive outpatients
compared to usual care in routine clinical practice.
Methods/design: The TBC-HTA study is a pragmatic randomized controlled study with a 6-month follow-up which
tests a TBC interprofessionnal intervention conducted among uncontrolled treated hypertensive outpatients in two
ambulatory clinics and among seven nearby community pharmacies in Lausanne and Geneva, Switzerland. A total
of 110 patients are being recruited and randomized to TBC (TBC: N = 55) or usual care group (UC: N = 55). Patients
allocated to the TBC group receive the TBC intervention conducted by an interprofessional team, involving an
ambulatory clinic nurse, a community pharmacist and a physician. A nurse and a community pharmacist meet patients
every 6 weeks to measure BP, to assess lifestyle, to estimate medication adherence, and to provide education to the
patient about disease, treatment and lifestyle. After each visit, the nurse and pharmacist write a summary report with
recommendations related to medication adherence, lifestyle, and changes in therapy. The physician then adjusts
antihypertensive therapy accordingly. Patients in the UC group receive usual routine care without sessions with a nurse
and a pharmacist. The primary outcome is the difference in daytime ambulatory BP between TBC and UC patients at
6-month of follow-up. Secondary outcomes include patients’ and healthcare professionals’ satisfaction with the TBC
intervention and BP control at 12 months (6 months after the end of the intervention).
Discussion: This ongoing study aims to evaluate the effect of a newly developed team-based care intervention
engaging different healthcare professionals on BP control in a primary care setting in Switzerland. The results will
inform policymakers on implementable strategies for routine clinical practice.
Trial registration: ClinicalTrials.gov registration: NCT02511093. Retrospectively registered on 28 July 2015.
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Background
High blood pressure (BP) is a major risk factor for
cardiovascular diseases (CVD) and mortality worldwide
[1]. Although treatment of hypertension can substan-
tially reduce this risk, hypertension remains under-
dected, undertreated, and poorly controlled [2, 3]. For
example, half of North American treated patients with
hypertension remain uncontrolled [4, 5]. A similar pro-
portion has been found in Switzerland [6]. Furthermore,
due to ageing populations, busy clinical workloads, and
shortage of physicians in most healthcare systems, new
approaches to hypertension care, involving pharmacists
[7, 8] or nurses [9, 10], could be a promising approach
to improve BP management and control.
Pharmacists are highly accessible healthcare profes-
sionals and indeed a valuable asset to improve hyperten-
sion management by providing medication management
in collaboration with physicians and by supporting
patients in medication intake [11–14]. Evidence supports
that pharmacists – working alone or in teams – are ef-
fective for the management of hypertension [13, 15–17]
and other CVD risk factors [16, 18, 19]. Nurses, by pro-
viding lifestyle counseling and health education, are also
helpful for the management chronic diseases [20, 21],
including hypertension [9, 22–24]. They are a valuable
member of team-based care at the interface between
patients and physicians [25]. Furthermore, nurses can
also intervene in collaboration with pharmacists to
improve BP as shown in a Canadian study and in
community-based prevention programs in Canada and
in the USA [26–30]. Santschi et al. demonstrated that a
collaborative model involving community pharmacists
and primary care physicians focused on the management
of drug adherence was feasible in the Swiss healthcare
system [31] and improved long-term BP control among
uncontrolled hypertensive patients [32].
Team-based care is a coordinated model of care
involving different healthcare professionals, such as phy-
sicians, pharmacists, nurses or other non-physician
clinicians, working in a collaborative partnership, each
with their own expertise [18, 25, 27]. Team-based care
of hypertension has recently been recommended by the
U.S Community Preventive Services Task Force [33, 34].
To this day, a team-based care, involving nurses and
community pharmacists working in collaboration with
physicians, to improve BP control need to be evaluated
in European countries, and in particular in Switzerland.
Therefore, we launched the Team-Based Care for im-
proving Hypertension management (TBC-HTA) random-
ized controlled study. This study is designed to evaluate if
a TBC interprofessional intervention, involving nurses and
community pharmacists working in collaboration with
physicians, improves BP control among uncontrolled
treated hypertensive patients under real-life conditions.
Methods/design
Study design and setting
The TBC-HTA study is an ongoing 3-year multicenter
pragmatic randomized controlled trial comparing a 6-
month team-based care interprofessional intervention,
involving nurses, community pharmacists and physicians,
to a usual care group among 110 outpatients followed in
ambulatory clinics and their nearby community pharma-
cies in Lausanne and Geneva areas, Switzerland (Fig. 1).
The patient is the unit of randomization and the unit of
analysis. We applied a pragmatic approach to determine
the effect of the TBC intervention under real-life condi-
tions with existing community healthcare professional
resources [35].
Treated uncontrolled hypertensive outpatients followed
in ambulatory clinics are recruited and randomly allocated
to one of two groups: 1) the TBC intervention group
(TBC: N = 55), in which patients receive care from nurses
and community pharmacists working in collaboration
with physicians; 2) the usual care group (UC: N = 55) in
which patients receive routine care without any interven-
tion from nurses or community pharmacists. Patients are
recruited from two ambulatory clinics: 1) the Hyperten-
sion Clinic, an outpatient clinic affiliated with Lausanne
University Hospital (CHUV; www.chuv.ch) and located in
Lausanne, 2) Cité générations, an ambulatory care center
located in Geneva (www.cite-generations.ch). Regular staff
nurses and physicians of the Hypertension Clinic and Cité
Générations are involved in the study. Nearby community
pharmacists in Lausanne and Geneva are recruited based
on their geographical proximity to the ambulatory clinics
to facilitate the follow-up of patients.
Participants
Identification and recruitment
Patients with the following inclusion criteria are eligible to
participate: 1) uncontrolled hypertension [defined as day-
time systolic ambulatory blood pressure measurement
(ABPM) ≥135 and/or diastolic ABPM ≥85 mmHg or office
systolic BP ≥140 and/or office diastolic ≥90 mmHg over at
least two consecutive visits [36]]; 2) taking at least one
antihypertensive medication; 3) aged 18 years old or more;
4) speak and understand French; and 5) agree to use the
service from the same pharmacy for the duration of the
study. Patients are excluded if they 1) are unable to under-
stand the study aim; 2) are pregnant or lactating; 3) live in
a nursing home; 4) are hospitalized; 5) participate in
another study; or 6) have daytime 24-h ABPM> 180/
110 mmHg. Eligible patients are contacted by phone by a
nurse who explains the study and ascertains the patient’s
willingness to participate. If the patient agrees to partici-
pate, the study information material is sent and an
appointment is scheduled by the nurse at the ambulatory
clinics. After consenting and completing the baseline
Santschi et al. BMC Cardiovascular Disorders  (2017) 17:39 Page 2 of 6
assessment, patients are randomized in a 1:1 allocation ra-
tio to the TBC intervention group or to the UC care group.
TBC intervention
The TBC interprofessional intervention, based on dis-
tinct competencies of healthcare professionals involved
in hypertension care, comprises:
1) A 2-h training workshop during which nurses and
community pharmacists are trained about the study
requirements, standardized BP measurement and
hypertension care according to the European Society
of Hypertension recommendations [36],
antihypertensive medication management (includ-
ing the assessment of medication adherence), and
counseling about lifestyle modification (physical
activity and diet);
2) Structured individual sessions conducted by
ambulatory clinic nurses at baseline, 6, 12 and
18-week and structured individual sessions
conducted by community pharmacists at baseline, 6,
12 and 18-week. Specifically, at each session, the
nurse measures BP, estimates adherence using the
Morisky Medication Adherence Scale (MMAS-8)
[37, 38], and provides lifestyle counseling (physical
activity and diet) during structured face-to-face
Fig. 1 Study Flow Diagram
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interviews with the patient. After each session,
the nurse sends a summary report (outlining BP
measurements, score of MMAS-8, physical activity
and diet assessment with any counselling and
recommendations) is sent by fax to the pharmacist.
The physician has access to this report. The patient
is then referred to the community pharmacist who
measures BP and emphasizes medication adherence
with the patient (using a specified guide following a
step process: gathering information from the patient,
creating a medication list, and identifying drug
related problems) during each structured individual
session. After each session, the pharmacist sends a
summary report (outlining BP measurement, score
of MMAS-8, and any recommendations to change
treatment) by fax to the nurse. The physician has
access to this report.
No medication change is allowed during the first 6 weeks
of follow-up. If BP is uncontrolled (≥140/90 mmHg) at
the 6, 12 and 18-week session with the community
pharmacist or the nurse, a contact (by phone or face-to-
face) with the physician is made by the nurse. Taking
account of the nurses’ and community pharmacists’
recommendations on lifestyle, medication adherence, and
therapy, the physician adapts the treatment if necessary.
Usual care group
Patients in the UC group received routine care by their
usual physician without nurse or community pharmacist
intervention.
Blood pressure measurement
At each visit, BP is measured in TBC patients by the
nurse and the community pharmacist using the clinically
validated Microlife WatchBP home oscillometric device
[39], using a standardized protocol. At the end of the 6-
month follow-up, ABPM is performed among TBC and
UC patients using the clinically validated electronic
Diasys device (DIASYS integra; Novacor SA, Rueil-
Malmaison, France) [40]. The ABPM device is installed
on the dominant arm by the nurse who explains the
procedure to the patient. Measurements are based on
the auscultatory mode, relayed by the oscillometric
mode in case of failure of the auscultatory mode. Mea-
surements are made every 20-min intervals during the
day and every 60-min intervals during the night [36].
The mean daytime ABPM is calculated from the average
of BP readings obtained between 9.30 am to 9.30 pm.
Outcomes
The primary outcomes are 1) the difference in mean
daytime ABPM at 6-month between TBC and UC
patients and 2) the difference in the proportion of
patients with controlled BP (daytime ABPM <135/
85 mmHg) at 6-month between TBC and UC patients.
Secondary outcomes include 1) patient’s and healthcare
professionals’ satisfaction with the TBC intervention
(using specified questionnaires administered at the end
of the follow-up); 2) the difference in the proportion of
TBC and UC patients with controlled BP (daytime
ABPM <135/85 mmHg) at 12 months (6 months after
the end of the intervention).
Sample size
Based on the results of our systematic review asses-
sing the impact of pharmacist interventions on BP
[41], a difference in systolic BP of 6 to 10 mmHg is
expected between TBC and UC care groups at the
end of 6 months of follow-up. A total of 46 patients
per group provides 80% power to detect a 6 mmHg
difference in systolic BP (SD: 10 mmHg) at 6-month
of follow-up with a two-sided alpha of 5%. Assuming
a drop-out or loss to follow-up rate of ~15%, the
sample size is adjusted to 55 per group, for a total
sample size of 110.
Randomization and blinding
Participants are randomized via a computer number
generator using sequentially numbered opaque sealed
envelopes in a 1:1 allocation ratio to either TBC or UC
group, using permuted blocks. The block sizes will not
be disclosed, to ensure concealment of allocation.
Assignments were made in advance by a statistician who
has prepared the sequentially numbered opaque sealed
envelopes that contain the randomization assignment.
Separate lists of randomization are produced for each
clinic. Numbered envelopes are opened after obtaining
each patient’s consent.
Study investigators, co-investigators and collaborators
are not informed of the randomization sequence. Due to
the nature of the intervention, patients and healthcare
professionals (physicians, nurses and community phar-
macists) cannot be blinded to the intervention.
Statistical analyses
All analyses will be conducted following the intention-
to-treat principle. The statistician will be blinded to
group allocation. Baseline characteristics of the TBC and
UC groups will be assessed via descriptive analyses in
terms of age, gender, co-morbidities, smoking status,
body mass index, BP and prescribed medications. Base-
line characteristics of nurses, pharmacists and physicians
will be also described, such as age, 6, year of graduation,
and pharmacist status (pharmacy owner, salaried em-
ployee). Means (standard deviations) and proportions
will be computed for continuous and categorical
variables, respectively.
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Mean systolic and diastolic BP at month-6 will be
compared between the study groups using a Student’s
two-sided t-test. At 6-month, the proportion of patients
with BP control (daytime ABPM <135/85 mmHg) will
be compared between the two groups using a chi-squared
test. To account for potential imbalances between groups,
multivariate linear or logistic regression will be used to
compare mean BP or odds of controlled BP at 6 months
between the TBC and UC groups, respectively. Two-sided
P value less than 0.05 will be considered as statistically
significant. Analyses will be made with Stata 13.0
software (StataCorp LP).
Discussion
The TBC-HTA randomized controlled study is ongoing
and will be the first attempt to evaluate a new approach
focused on a team-based care intervention engaging
different healthcare professionals to improve BP control
in a primary care setting in Switzerland. The results of
the current study will complete knowledge in the team-
based care approach but also inform policymakers on
implementable strategies in the future. Indeed, this study
could make a significant contribution to various health-
care systems in terms of efficacy and possible implemen-
tation and dissemination of a collaborative approach for
hypertension management.
There are potential limitations to this study. Only 2
ambulatory clinics participate in the study. In addition,
these ambulatory clinics were selected because they were
interested in implementing the TBC interprofessional
intervention in their clinical practice. This could limit
the external validity of the study. However, the fact that
the study is conducted under real-life conditions with
existing community healthcare professional resources,
increases the generalizability and the possibility of
disseminating the intervention (if effective) in primary
care settings.
The value of this study could be enhanced by an
economic analysis, integrating an estimate of patient
contact time by the nurses, community pharmacists
and physicians. This analysis could offer policy
makers compelling arguments for the dissemination
of the TBC intervention. Therefore, as secondary and
exploratory analyses, we will make some estimations
of the cost of the intervention.
Although the Swiss healthcare system has character-
istics which may hidden the generalizability of our
findings, our results combined with those of other
similar studies should provide impetus for the gradual
dissemination of the TBC model to other settings and
countries with a high burden of hypertension and
shortage of physicians.
Strengths of the TBC-HTA study include its design as
a RCT and the use of existing community healthcare
professional resources in real-life conditions to evaluate
the collaborative approach. In addition, TBC model of
hypertension care could offer opportunities for efficient
approach to hypertension treatment and control in
real-life conditions and will inform policy makers on
strategies to implement.
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